Diffuse large B-cell lymphoma trials in Chile
4 trials · From ClinicalTrials.gov, checked 11 November 2026. Ask the study team whether a trial fits you.
- Phase 3Taking peopleA Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
- Where
- Concepción, La Serena, Santiago, Valdivia, Viña del Mar
- Age
- 18 years and over
- People
- 1,046 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06717347 · EU 2024-515566-13-00 - Phase 3Taking peopleA Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma
- Where
- Santiago
- Age
- 18 years and over
- People
- 904 worldwide
- Run by
- Regeneron Pharmaceuticals
See details and how to joinNCT06091865 · EU 2022-502785-25-00 - Phase 2/3Taking peopleA Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)
- Where
- Concepción, La Serena, Santiago, Valdivia
- Age
- 18 years and over
- People
- 290 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT05139017 · EU 2022-502646-27-00 - Phase 1/2Taking peopleSubstudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
- Where
- Concepción, Santiago, Valparaíso
- Age
- 6 months to 25 years
- People
- 90 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06395103 · EU 2023-507178-41-00